SCOPUS 정보 검색 플랫폼

Volumn 92, Issue 12, 1998, Pages 4778-4791

Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: Role of interleukin-6 and macrophage colony- stimulating factor

(7) Menetrier Caux, C b Montmain, G b Dieu, M C b Bain, C b Favrot, M C b Caux, C b Blay, J Y a

a CENTRE LÉON BÉRARD (France)

b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 6 RECEPTOR; RECOMBINANT COLONY STIMULATING FACTOR 1; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 6;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL SUBPOPULATION; CONTROLLED STUDY; DENDRITIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MONOCYTE; PHAGOCYTE; PRIORITY JOURNAL; TUMOR ESCAPE;

EID: 0032535002 PISSN: 00064971 EISSN: None Source Type: Journal
DOI: 10.1182/blood.v92.12.4778.424k14_4778_4791 Document Type: Article

Times cited : (515)

References (5)

1
- 0024849183
- Combination therapy with interleukin-2 and a interferon for the treatment of patients with advanced cancer
- Rosenberg SA, White DE, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE: Combination therapy with interleukin-2 and a interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863, 1989
- (1989) J Clin Oncol , vol.7 , pp. 1863
- Rosenberg, S.A.¹ White, D.E.² Lotze, M.T.³ Yang, J.C.⁴ Linehan, W.M.⁵ Seipp, C.⁶ Calabro, S.⁷ Karp, S.E.⁸ Sherry, R.M.⁹ Steinberg, S.¹⁰ White, D.E.¹¹

2
- 0008397025
- The FNCLCC CRECY trial: Interleukin 2 (IL2) + interferon (IFN)-α is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC)
- abstr
- Négrier S, Escudier B, Lasset C, Savary J, Chevreau C, Ravaud A, Peny J, Mousseau M: The FNCLCC CRECY trial: Interleukin 2 (IL2) + interferon (IFN)-α is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 15:248, 1996 (abstr)
- (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 248
- Négrier, S.¹ Escudier, B.² Lasset, C.³ Savary, J.⁴ Chevreau, C.⁵ Ravaud, A.⁶ Peny, J.⁷ Mousseau, M.⁸

3
- 0027369122
- Tumor specific lysis of human renal cell carcinomas by tumor infiltrating lymphocytes. I-HLA-A2 restricted recognition of autologous and allogeneic tumor lines
- Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G, Segurado OG: Tumor specific lysis of human renal cell carcinomas by tumor infiltrating lymphocytes. I-HLA-A2 restricted recognition of autologous and allogeneic tumor lines. J Immunol 151:409, 1993
- (1993) J Immunol , vol.151 , pp. 409
- Schendel, D.J.¹ Gansbacher, B.² Oberneder, R.³ Kriegmair, M.⁴ Hofstetter, A.⁵ Riethmüller, G.⁶ Segurado, O.G.⁷

4
- 0028560439
- Cellular immune response to human renal cell carcinoma: Definition of a common antigen recognized by HLA-A2 restricted cytotoxic T lymphocyte (CTL) clones
- Bernhard H, Karbach J, Wölfel T, Busch P, Störkel S, Stöckle M, Wölfel C, Seliger B, Huber C, Meyer zum Büschenfelde KH: Cellular immune response to human renal cell carcinoma: Definition of a common antigen recognized by HLA-A2 restricted cytotoxic T lymphocyte (CTL) clones. Int J Cancer 59:837, 1994
- (1994) Int J Cancer , vol.59 , pp. 837
- Bernhard, H.¹ Karbach, J.² Wölfel, T.³ Busch, P.⁴ Störkel, S.⁵ Stöckle, M.⁶ Wölfel, C.⁷ Seliger, B.⁸ Huber, C.⁹ Meyer Zum Büschenfelde, K.H.¹⁰

5
- 0029939743
- A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma
- Brändle D, Brasseur F, Weynants P, Boon T, Van Den Eynde BJ: A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 183:2501, 1996
- (1996) J Exp Med , vol.183 , pp. 2501
- Brändle, D.¹ Brasseur, F.² Weynants, P.³ Boon, T.⁴ Van Den Eynde, B.J.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.